William Blair analyst Matt Phipps reiterated a Buy rating on Autolus Therapeutics (AUTL – Research Report) on May 16. The company's shares closed last Friday at $2.74, close to its 52-week low of $2.20. According to TipRanks.com, Phipps has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.1% and a 36.3% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Chinook Therapeutics, Kezar Life Sciences, and Jasper Therapeutics. Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $14.00, representing a 389.5% upside.
https://www.tipranks.com/news/blurbs/william-blair-reiterates-their-buy-rating-on-autolus-therapeutics-autl?utm_source=advfn.com&utm_medium=referral
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2023 to Mar 2023 Click Here for more Autolus Therapeutics Charts.
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Autolus Therapeutics Charts.